By Nigel Somerville, the Deputy Sheriff of AIM | Tuesday 29 January 2019
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Noting that one of Neil Woodford’s earliest investments for Woodford Patient Capital Trust (WPCT), Verseon (VSN) – trading on AIM but a US biotech outfit in the disruptive space (natch) – appears to be headed for trouble I commented that at least the company has the services of the good Xavier Rolet (yes, the former LSE boss!) on the board. So all’s well! Well, it was until this morning! Oh dear….
Already registered? Click here to sign in
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen